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Abstract 
Objectives: The objective was to investigate the serial mediating effects of perceived cognitive 
functioning and pain interference in daily living in the relationship between perceived pain and 
overall generic health-related quality of life (HRQOL) in children, adolescents, and young adults 
with Neurofibromatosis Type 1 (NF1). 
Methods:  The Pain, Cognitive Functioning, and Pain Impact Scales from the PedsQL 
Neurofibromatosis Type 1 Module and the PedsQL 4.0 Generic Core Scales were completed in a 
multi-site national study by 323 patients ages 5-25 and 335 parents. A serial multiple mediator 
model analysis was conducted to test the hypothesized sequential mediating effects of perceived 
cognitive functioning and pain interference as intervening variables in the association between 
pain as a predictor and HRQOL. 
Results: Pain predictive effects on overall generic HRQOL were serially mediated by perceived 
cognitive functioning and pain interference. In predictive analytics models utilizing hierarchical 
multiple regression analyses with age and gender demographic covariates, pain, perceived 
cognitive functioning and pain interference accounted for 66 percent of the variance in patient-
reported generic HRQOL and 57 percent of the variance in parent proxy-reported generic 
HRQOL (P < 0.001), reflecting large effect sizes. 
Conclusions: Perceived cognitive functioning and pain interference explain in part the 
mechanism of pain predictive effects on overall generic HRQOL in pediatric patients with NF1. 
Identifying NF1-specific pain, perceived cognitive functioning, and pain interference as salient 
predictors of overall generic HRQOL from the patient and parent perspective facilitates a family-
centered orientation to the comprehensive care of children, adolescents, and young adults with 
NF1.  
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Introduction 
Neurofibromatosis Type 1 (NF1) is a single-gene neurocutaneous disorder caused by a 
mutation in the gene encoding neurofibromin, and is the most common autosomal dominant 
disorder of the nervous system.1-3 As a complex neurogenic chronic condition with wide 
variability in clinical manifestations,1,4-6 NF1 can impact the central and peripheral nervous 
systems, with a predisposition toward the development of benign and malignant nervous system 
tumors.7,8 Plexiform neurofibromas (peripheral nerve sheath tumors) are estimated to occur in 
approximately 25 to 50 percent of pediatric patients, with both asymptomatic and symptomatic 
plexiform neurofibromas manifested.9,10  Further, NF1 has been demonstrated to have a 
significantly adverse impact on generic (general or nondisease-specific) health-related quality of 
life (HRQOL) in pediatric patients.11 
Chronic and recurrent pain has been found to be a highly prevalent symptom in pediatric 
and adult patients with NF1, including peripheral neuropathic pain and headaches.12-15 One of the 
major causes of neurogenic pain in NF1 are plexiform neurofibromas.10,12,14 Prior research has 
shown that pain has a negative effect on overall generic HRQOL in pediatric chronic pain 
populations.16-18 Additionally, the concept of “ pain impact” or “pain interference” has emerged 
as a construct that measures pain-specific impact or interference with daily functioning.16,19 The 
items in pain impact/interference scales include specific reference to the interference or impact 
caused by pain on daily activities.19 Although these measures are typically multi-item scales, a 
recent study of pain interference in NF1 used a single item from an existing scale that was 
predictive of lower functioning.20 
Cognitive functioning problems have also been identified as prevalent neurogenic 
manifestations in pediatric patients with NF1.21 These neurocognitive deficits include difficulties 
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in executive functioning, memory problems, attention deficits, learning disabilities, and overall 
intellectual performance typically evidenced in the low average range, with moderate to severe 
impairment in one or more areas of cognitive functioning affected.3,22,23 Estimated rates of 
cognitive dysfunction vary widely, with estimates ranging from 20 percent to as high as 80 
percent of patients with NF1.21,24   
Past research with other patient populations has demonstrated that chronic and recurrent 
pain has a deleterious effect on cognitive functioning.25,26 Thus, while it would be expected that 
cognitive functioning problems in pediatric patients with NF1 would be exhibited as a 
consequence of their chronic health condition, it may be hypothesized that similar to other 
patient populations, pain would also have an additional deleterious direct effect on perceived 
cognitive functioning in these patients. 
Previously, we investigated the direct effects of pain as a predictor variable of overall 
generic HRQOL in children, adolescents, and young adults with NF1.27 A distinctive feature of 
the study was the inclusion of NF1-specific multi-item measurement scales developed 
specifically for NF1 through extensive cognitive interviews with children, adolescents, and 
young adults with NF1 and their parents,28 rather than utilizing generic measures of these 
constructs. These NF1-specific multi-item measurement scales were subsequently nationally 
tested during the PedsQL Neurofibromatosis Type 1 Module field test study, demonstrating 
excellent reliability and validity.29 
Nonetheless, unique to the current study, we are not aware of prior research which has 
investigated the hypothesized mechanism that may explain in part the predictive effects of pain 
on overall generic HRQOL in pediatric patients with NF1 utilizing an a priori conceptual model 
that includes NF1-specific perceived cognitive functioning and pain interference in daily living 
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as hypothesized sequential mediating variables. By understanding the mechanism in which pain 
affects overall generic HRQOL, treatment strategies may be developed to ameliorate in part the 
negative impact of NF1-specific pain on overall HRQOL by targeting the hypothesized 
intervening variables that may be potentially modifiable.  
 To address this significant empirical gap in the pediatric NF1 research literature, we 
utilized the database from the PedsQL Neurofibromatosis Type 1 Module field test study to test 
the hypothesized mediators of pain predictive effects on overall total generic HRQOL in 
pediatric patients with NF1. We investigate a serial multiple mediator conceptual model in which 
the serial (sequential) mediating effects of perceived cognitive functioning and pain interference 
in daily living are hypothesized as intervening variables in the relationship between pain and 
overall generic HRQOL. We conducted a serial multiple mediator analysis to test the following 
hypothesized conceptual model: pain → perceived cognitive functioning → pain interference in 
daily living → overall generic HRQOL in which the predictive effects of pain on generic 
HRQOL are mediated sequentially by perceived cognitive functioning and pain interference in 
daily living.    
Methods 
Participants and Settings 
Pediatric patients with physician-diagnosed NF1 using the National Institutes of Health 
diagnostic criteria were recruited across the United States. Participants were recruited through 
the Children’s Tumor Foundation (CTF) Neurofibromatosis (NF) registry, NF clinics at Indiana, 
Michigan, California, and Washington, D.C., and NF organizations including the Texas NF 
foundation, NF mid-west and NF network forums. A total of 343 families (323 pediatric patients 
ages 5-25 and 335 parents) participated.29  Families completed the PedsQL measurement 
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instruments either using paper mode of administration (n = 204, 59.5%) at home or Internet 
electronic model of administration at home (n =139, 40.5%). The average age of the 169 males 
(49.3%) and 174 females (50.7%) was 12.38 years (SD = 5.89). With respect to race/ethnicity, 
the sample contained 256 (74.6%) White non-Hispanic, 23 (6.7%) Hispanic, 14 (4.1%) Black 
non-Hispanic, 3 (0.9 %) Asian/Pacific Islander, 1 Native American (0.3%), 30 (8.7%) Other, and 
16 (4.7%) missing. Data collection for the field test took place between September 2015 and 
December 2016.29 Parental informed consent and patient assent/consent (when age appropriate) 
were obtained. The research protocol was approved by the Institutional Review Board at Indiana 
University, Indianapolis (protocol # 1403632840). 
Measures 
PedsQL Neurofibromatosis Type 1 Module  
The PedsQL Neurofibromatosis Type 1 Module items and scales were developed through 
qualitative and quantitative methods with pediatric patients with NF1 and their parents.28,29 The 
PedsQL NF1 Module items were developed using detailed qualitative methods as recommended 
by the FDA30 and the patient-reported outcomes (PRO) measurement literature,31 including 
individual cognitive interviews with patients and parents.28,32 Based on the readability, clarity, 
and understandability of the items as perceived by the patients and parents, changes were made 
until no further changes were recommended by patients and parents, including the youngest 
patients.28 
To measure the NF1-specific constructs for the present study, we utilized the following 
scales from the PedsQL Neurofibromatosis Type 1 Module: Pain Scale (6 items, e.g., “I have 
pain so much that I need medicine”), Cognitive Functioning Scale (15 items, e.g., “It is hard for 
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me to think quickly”), and Pain Impact Scale (16 items, e.g., “I have so much pain that I have to 
stop what I am doing”).  
The format, instructions, Likert response scale, and scoring method for the PedsQL 
Neurofibromatosis Type 1 Module scales are identical to the PedsQL 4.0 Generic Core Scales,33 
with higher scores indicating better HRQOL and hence lower symptoms and problems. The 
scales are comprised of parallel patient self-report and parent proxy-report formats. Patient self-
report and parent proxy-report forms are specific for ages 5-7 (young child), 8-12 (child), 13-17 
(adolescent), and 18-25 (young adult) and assess patient’s and parent’s perceptions of the 
patient’s NF1-specific symptoms and problems. The items for each of the forms are essentially 
identical, differing in developmentally appropriate language, or first or third person tense. The 
instructions ask how much of a problem each item has been during the past 7 days using the 
PedsQL 5-point Likert-type response scale (0 = never a problem; 1 = almost never a problem; 2 
= sometimes a problem; 3 = often a problem; 4 = almost always a problem). To further increase 
the ease of use for the young child self-report (ages 5-7), the response scale is reworded and 
simplified to a 3-point scale (0 = not at all a problem; 2 = sometimes a problem; 4 = a lot of a 
problem). This simplification to a 3-point scale for the young child self-report is consistent with 
the PedsQL 4.0 Generic Core Scales as well as with all of the PedsQL disease-specific 
modules.34  
Items are reverse-scored and linearly transformed to a 0-100 scale (0=100, 1=75, 2=50, 
3=25, 4=0), so that lower scores demonstrate more NF1 symptoms and problems and hence 
lower NF1-specific HRQOL. Scale Scores are computed as the sum of the items divided by the 
number of items answered (this accounts for missing data). If more than 50% of the items in the 
scale are missing, the Scale Score is not computed.35  This accounts for the small differences in 
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sample sizes for some scales reported in the analyses. Although there are other strategies for 
imputing missing values, this computation is consistent with the previous PedsQL peer-reviewed 
publications as well as other well-established HRQOL measures.34 
PedsQL 4.0 Generic Core Scales 
The 23-item PedsQL 4.0 Generic Core Scales encompass: 1) Physical Functioning (8 
items), 2) Emotional Functioning (5 items), 3) Social Functioning (5 items), and 4) School 
Functioning (5 items).33,36 To create the Total Scale Score, the mean is computed as the sum of 
the items divided by the number of items answered in the Physical, Emotional, Social, and 
School Functioning Scales. The Total Scale Score measures overall generic HRQOL.33 Higher 
scores indicate better HRQOL.  
PedsQL Family Information Form 
 Participants completed the PedsQL Family Information Form which contains 
demographic information including the child’s age, gender, and race/ethnicity.33    
Statistical Analysis 
Pearson product-moment correlation analyses were conducted to test the bivariate 
associations between the Pain, Cognitive Functioning, and Pain Impact Scales with the Generic 
Core Scales Total Scale Score. Bivariate correlation effect sizes are designated as small (0.10), 
medium (0.30), and large (0.50) in magnitude.37 Predictive analytics models utilizing 
hierarchical multiple regression analyses were conducted to statistically predict the Generic Core 
Scales Total Scale Score by the Pain, Cognitive Functioning, and Pain Impact Scales after 
controlling for age and gender.38 Age and gender, but not race/ethnicity, have been previously 
demonstrated to be statistically significant in univariate analyses with the Generic Core Scales 
Total Scale Score dependent variable for this database,27 and hence are entered as demographic 
covariates in the multivariate analyses. Hierarchical multiple regression analyses tested the 
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change in the variance accounted for by perceived pain in Step 2, and cognitive functioning and 
pain interference in Step 3 (R2 changes) after controlling for age and gender (coded male=1, 
female=2) in Step 1. R2 values are reported for each step and the full model. Total R2 is the 
percentage of variability in the outcome variable (HRQOL) explained by the full model 
(demographic covariates, predictor, mediators). R2 effect sizes are designated as small (0.02), 
medium (0.13), and large (0.26) in magnitude.37 These statistical analyses were conducted using 
IBM SPSS (Armonk, New York). 
Mediator variables are hypothesized as the intervening mechanism to account in part for 
the relationship between a predictor variable and an outcome variable.39,40 The predictor variable 
is hypothesized to have a direct effect on the outcome variable, as well as a potentially indirect 
effect through the mediator variables, which may clarify the mechanism linking the predictor 
variable to the outcome. 
A serial multiple mediator model 41 was tested with perceived cognitive functioning and 
pain interference in daily living as hypothesized sequential mediators in the relationship between 
pain as a predictor variable and overall generic HRQOL as the outcome variable. Specifically, 
we tested the following serial multiple mediator model: pain → perceived cognitive functioning 
→ pain interference in daily living → overall generic HRQOL. Indirect effects were tested 
utilizing 10,000 bias-corrected bootstrapped resamples with replacement yielding 95% 
confidence intervals. Significant indirect effects are demonstrated when the 95% confidence 
intervals do not include zero.41 These analyses were conducted using the PROCESS macro for 
SPSS (processmacro.org) as described in Hayes.42                                                                           
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Results 
Bivariate Intercorrelations between Pain, Cognitive Functioning, and Pain 
Impact/Interference Scales with Generic Core Scales Total Scale Score 
 Table 1 contains the means, standard deviations and bivariate correlations of the Pain, 
Cognitive Functioning, and Pain Impact (Interference) Scales with the Generic Core Total Scale 
Score for patient self-report and parent proxy-report. The Pain, Cognitive Functioning, and Pain 
Impact (Interference) Scales were significantly correlated with the Generic Core Scales Total 
Scale Score (all Ps < 0.001), demonstrating large effect sizes. 
Correlational analyses and independent samples t-tests were conducted to explore 
whether there were any significant age correlations or gender differences in the PedsQL NF1 
Module scales for patient self-report and parent proxy-report. For patient self-report, increasing 
age was significantly correlated with lower (worse) Pain Scale scores (r = -0.37, P < 0.001), 
Cognitive Functioning Scale scores (r = -0.13, P < 0.05), and Pain Impact (Interference) Scale 
scores (r = -0.26, P < 0.001). For parent proxy-report, increasing age was significantly correlated 
with lower (worse) Pain Scale scores (r = -0.33, P < 0.001) and Pain Impact (Interference) Scale 
scores (r = -0.28, P < 0.001), but not Cognitive Functioning Scale scores (r = -0.09, P > 0.05).  
For patient self-report, females reported lower (worse) scores than males on the Pain 
Scale (59.76 vs. 73.11, t[321] = -4.71, P < 0.001) and the Pain Impact (Interference) Scale (69.84 
vs. 77.47, t[320] = -2.68, P < 0.01), but not the Cognitive Functioning Scale (55.57 vs. 60.14, 
t[319] = -1.49, P > 0.05). For parent proxy-report, females were reported as manifesting lower 
(worse) scores than males on the Pain Scale (62.22 vs. 71.43, t[331] = -3.26, P < 0.001) and the 
Pain Impact (Interference) Scale (71.49 vs. 80.14, t[330] = -3.14, P < 0.01), but not the 
Cognitive Functioning Scale (52.55 vs. 49.86, t[330] = 0.89, P > 0.05). 
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Hierarchical Multiple Regression Analysis Predicting Generic HRQOL 
A hierarchical multiple regression analysis was conducted prior to the serial multiple 
mediator model analysis to determine the percentage of the variance accounted for in the Generic 
Core Scales Total Scale Score by the pain predictor variable and the perceived cognitive 
functioning and pain interference mediator variables after controlling for age and gender. As 
shown in Table 2, pain accounted for 38 percent of the variability in patient self-reported generic 
HRQOL and 34 percent of the variability in parent proxy-reported generic HRQOL in Step 2, 
after accounting for age and gender in Step 1. The perceived cognitive functioning and pain 
interference mediator variables together accounted for an additional 25 percent of the variability 
in patient self-reported generic HRQOL and 21 percent of the variability in parent proxy-
reported generic HRQOL in Step 3, after accounting for the demographic covariates and pain 
predictor variable in Steps 1 and 2, respectively.    
Serial Multiple Mediator Model Predicting Generic HRQOL 
 Controlling for age and gender, the serial multiple mediator model demonstrated that the 
total indirect effect of the pain predictor variable on generic HRQOL as estimated by the sum of 
the indirect effects for perceived cognitive functioning and pain interference was .4303 for 
patient self-report and .3835 for parent proxy-report, and different from zero as determined by 
the bias-corrected bootstrap 95% confidence intervals that were above zero for patient self-report 
(.3440, .5214) and parent proxy-report (.2617, .5034). Within the multiple mediator model, the 
serial indirect effects for pain → perceived cognitive functioning → pain interference in daily 
living → overall generic HRQOL was .0262 for patient self-report and .0088 for parent proxy-
report, and the bias-corrected bootstrap 95% confidence intervals did not contain zero for patient 
self-report (.0130, .0455) and parent proxy-report (.0022, .0205). The full serial multiple 
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mediator model accounted for 66 percent of the variability for patient self-report generic 
HRQOL and 57 percent of the variability for parent proxy-report generic HRQOL (P < 0.001), 
demonstrating large effect sizes (see Table 2).        
 
Discussion 
 The findings demonstrate that perceived cognitive functioning and pain-specific 
interference in daily living serially mediate the association between pain and overall generic 
HRQOL in pediatric and young adult patients with NF1. The mediators as a group (perceived 
cognitive functioning and pain interference in daily living) contributed an additional 25 percent 
of the variance in patient self-reported generic HRQOL and an additional 21 percent of the 
variance in parent proxy-reported HRQOL for their children beyond the direct effects of pain. 
These are unique findings not previously reported in the published empirical literature for 
pediatric and young adult patients with NF1. The full serial multiple mediator model accounted 
for 66 and 57 percent of the variance in overall generic HRQOL from the perspective of patients 
with NF1 and their parents, respectively, reflecting large effect sizes.  
As comprehensively reviewed by Moriarty and colleagues, there are a number of theories 
postulated to delineate the pathophysiological mechanisms involved in the negative effect of 
chronic and recurrent pain on cognitive functioning.25 These hypotheses include the competing 
of nociceptive stimuli for attentional resources, central nervous system neuroplastic changes 
resulting from persistent pain that undermine cognitive functioning, and neurochemical adverse 
effects that are a function of chronic and recurrent pain that interference with cognitive 
functioning. These theories as extensively reviewed by Moriarty et al. have varying levels of 
empirical support, with no one theory predominate in human or animal models.25 It is essential to 
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note that even though patients with NF1 demonstrate brain structural abnormalities and 
differences in neural activation patterns within brain regions (in comparison to typically 
developing controls) that may be associated with cognitive impairment,43-45 we hypothesized in 
developing our serial multiple mediator conceptual model that the experience of chronic and 
recurrent pain would additively further comprise perceived cognitive functioning in these 
patients. Thus, we hypothesized that individuals with NF1 are at even greater risk for cognitive 
impairment as a result of their pain experiences. Future research utilizing functional magnetic 
resonance imaging (fMRI)44 and other pain research strategies,26,46,47 will be needed to 
disentangle the complexities of pre-existing cognitive impairment and the potentially additional 
direct effects of pain on cognitive functioning in pediatric patients and young adults with NF1. 
In the present study, the serial multiple mediator conceptual model further illustrates the 
complex relationship between perceived pain and overall generic HRQOL and may explain in 
part the mechanism linking pain to generic HRQOL. This conceptual model identifies potentially 
modifiable targets for treatment interventions to improve impaired generic HRQOL in pediatric 
patients with NF1. Specifically, chronic pain management strategies, including cognitive 
behavioral therapy techniques,48 may help lessen the negative direct effects of pain on perceived 
cognitive functioning in pediatric patients with NF1, which in turn may reduce the negative 
effect of pain and perceived cognitive functioning on pain-specific interference in daily 
functioning, and subsequently in combination lessen the negative impact on overall generic 
HRQOL. Further, pharmaceutical interventions may facilitate coping with the attentional deficits 
in pediatric patients with NF1.49 These emerging interventions for pediatric patients with NF1 
may serve as important components of a comprehensive care approach in improving overall 
15 
 
HRQOL in these patients. Further intervention research will be necessary to determine the 
potential efficacy of these intervention strategies in pediatric patients with NF1. 
The overall generic HRQOL in the present sample as measured by the PedsQL 4.0 
Generic Core Scales is substantially impaired as evidenced by patient self-report and parent 
proxy-report, with the Total Scale Score of 65.47 for patient self-report being close to 20 points 
lower than published PedsQL data for healthy pediatric populations (83.84), while the parent 
proxy-report score of 63.47 is also substantially lower than healthy comparison data (82.70).50 
Though these scores are not matched for age and gender with the published healthy comparison  
data, they nevertheless provide a relative benchmark of impaired overall functioning.   
The present study strengths include the inclusive age range of ages 5-25 years, the large 
sample size for this rare disease, the nationwide recruitment, and the testing of a unique 
predictive analytics model with NF1-specific pain, perceived cognitive functioning, and pain 
interference in daily living constructs as predictor and mediator variables. The inclusion of both 
patient self-report and parent proxy-report further increases the strength of the data although 
shared method variance may limit the generalizability of the findings since it may have inflated 
the associations among constructs. Additional limitations include the absence of information in 
the database regarding the characteristics of any families who declined participation, the sample 
was predominantly White non-Hispanic which may limit the generalizability of the findings to 
other race/ethnicity groups, and the existing database did not contain information on whether the 
children were in school at the time the measures were completed. Although parents were 
instructed that it was important for parents and children to complete the forms separately, given 
that the forms were completed at home, we were not able to monitor whether these instructions 
were followed. Additionally, no specific instructions were given to parents regarding form 
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administration if their child had a learning disability. Although participants completed the 
PedsQL using either paper or Internet electronic modes of administration, previous PedsQL 
research has demonstrated the measurement equivalence of these two modes of administration.51    
 The existing database also lacked data on specific clinical subgroups of patients such as 
those with plexiform neurofibromas.10 Further, we do not have in the field test database 
information on the number of patients who were diagnosed with brain tumors.52 However, it is 
important to note that there are neurocognitive deficits manifested by pediatric patients with NF1 
that are not secondary to brain tumors, but which may result from minor brain malformations, 
white matter structural abnormalities and deficient neural response inhibition.43,44,53,54 Thus, even 
in patients with NF1 who have not developed brain tumors, neurocognitive deficits may be 
manifested. We also do not have in our field test database information on the number of patients 
who received a comorbid diagnosis of attention-deficit-hyperactivity disorder (ADHD). 
However, executive functioning deficits have been found to be manifested in pediatric patient 
with NF1 regardless of whether they have received a comorbid diagnosis of ADHD,55 suggesting 
that executive functioning deficits exist even in patients who are not diagnosed with ADHD. 
Lastly, it should be noted that the PedsQL Neurofibromatosis Module Cognitive Functioning 
Scale is a patient self-report and parent proxy-reported measure of perceived cognitive 
functioning. Recent research with adults with neuropathic pain found that pain was predictive of 
cognitive functioning as measured by neurocognitive subtests of standardized intelligence tests, 
particularly impacting memory and attention.26 Nevertheless, whether generic measures of 
neurocognitive functioning such as those contained in standardized intelligence tests would 
generate similar findings as the current study in pediatric patients with NF1 is an area for future 
research.  
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In conclusion, the findings with these NF1-specific scales indicate that a serial 
(sequential) multiple mediator intervening mechanism explains in part how perceived pain may 
predict overall generic HRQOL in pediatric patients with NF1. This serial multiple mediator 
conceptual model and its findings may facilitate the development of future targeted interventions 
to improve the health and well-being of these pediatric and young adult patients. Further, the 
systematic utilization of NF1-specific measurement scales in clinical research and clinical 
practice may be imperative in identifying those patients who are in the greatest need of 
symptom-specific interventions to enhance their overall HRQOL. 
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Table 1. PedsQL Neurofibromatosis Scales and Generic Core Scales Total Scale Score 
Bivariate Intercorrelations in Pediatric Patients with Neurofibromatosis Type 1 
 
Neurofibromatosis Scales and Generic 
Core Scales Total Scale Score 
 
Items 
 
α 
 
Mean 
 
SD 
 
r*1 
 
r*2 
 
r*3 
 
r*4 
Symptoms         
 Pain 6 0.87 66.12 26.48 0.15a 0.49* 0.55* 0.64* 
 Skin Itch Bother 6 0.84 76.71 21.75 0.28* 0.31* 0.33* 0.55* 
 Skin Sensations 3 0.82 83.64 22.61 0.17* 0.31* 0.38* 0.50* 
Mediators         
 Speech Difficulties 4 0.93 64.89 30.22 __ 0.33* 0.21* 0.42* 
 Health Communication 6 0.92 58.59 32.65 __ __ 0.68* 0.59* 
 Worry 10 0.93 65.33 29.70 __ __ __ 0.61* 
Generic Core Total Scale Score 23 0.93 65.65 20.84 __ __ __ __ 
 
Note: *All Ps < 0.001, except a P < 0.01.  
SD = standard deviation. α = Cronbach’s alpha internal consistency reliability. 
r = Pearson product-moment correlation coefficient. Dash line = not applicable. 
1Bivariate correlations with Speech Difficulties. 
2Bivariate correlations with Health Communication. 
3Bivariate correlations with Worry. 
4Bivariate correlations with the Generic Core Scales Total Scale Score. 
Effect sizes for Pearson r designated as small (0.10), medium (0.30), and large (0.50) in magnitude. 
Lower scores demonstrate worse symptoms and problems.  
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Hierarchical Multiple Regression Analyses with the Mediators Variables Predicting 
Generic Core Scales Total Scale Score Controlling for the Symptoms Predictors, Age, and 
Gender in Step 1 (data not shown) 
 
 
Mediator Variables 
 
 
Regression Values 
Pain Predictor Model Step 2 
 
Speech Difficulties (β) 
 
Health Communication (β) 
 
Worry (β) 
                            
R2 change 
 
R2 Full Model 
 
 
 
0.24* 
 
0.16a 
 
0.25* 
 
0.19* 
 
0.61* 
 
Skin Itch Bother Predictor Model Step 2 
 
Speech Difficulties (β) 
 
Health Communication (β) 
 
Worry (β) 
                            
R2 change 
 
R2 Full Model 
 
 
 
0.21* 
 
0.20* 
 
0.29* 
 
0.23* 
 
0.59* 
 
Skin Sensations Predictor Model Step 2 
 
Speech Difficulties (β) 
 
Health Communication (β) 
 
Worry (β) 
                            
R2 change 
 
 
 
 
0.24* 
 
0.22* 
 
0.31* 
 
0.30* 
R2 Full Model  
0.56* 
 
Note: *All Ps < 0.001, except a P < 0.01. 
β = Standardized regression coefficients (beta weights). 
R2 =Percentage of variability in the criterion variable (HRQOL) explained by the step. 
R2 effect sizes designated as small (0.02), medium (0.13), and large (0.26) in magnitude.  
 
 
 
